Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.83.

A number of brokerages have recently commented on AQST. Leerink Partnrs raised Aquestive Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. Piper Sandler began coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Friday, July 26th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Finally, SVB Leerink began coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $8.00 target price for the company.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds have recently modified their holdings of the company. Financial Advocates Investment Management lifted its position in shares of Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $594,000. Virtu Financial LLC lifted its position in shares of Aquestive Therapeutics by 219.7% in the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after acquiring an additional 70,666 shares during the period. Lazard Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares during the period. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $3.80 on Wednesday. The firm has a market cap of $345.95 million, a price-to-earnings ratio of -9.05 and a beta of 2.81. The business’s 50-day simple moving average is $2.86 and its 200-day simple moving average is $3.32. Aquestive Therapeutics has a 52 week low of $1.25 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $12.22 million. During the same quarter last year, the company posted $0.11 earnings per share. As a group, equities research analysts forecast that Aquestive Therapeutics will post -0.49 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.